A woman from Gaza who received a cancer diagnosis in 2020 says she has been unable to continue treatment because the Palestinian Authority (PA) is unable to fund care after Israel withheld tax revenues, demonstrating how fiscal measures linked to the conflict have direct consequences for patients in the occupied West Bank.
Patient trapped between medical need and political impasse
The patient, identified in reporting as Um Mahmoud*, told journalists she considers herself “one of the lucky few” because she was in Ramallah for treatment when the conflict in Gaza intensified in October 2023. Nearly three years on, she remains unable to obtain the oncology care she needs locally.
“One of the lucky few.”
According to the report, her situation has been compounded by a change in the PA’s ability to fund patients’ treatment after Israeli authorities detained tax transfers that the PA depends upon. As a result, patients who previously received payments or referrals for treatment have faced lengthy delays or outright denial of services.
How the financial squeeze affects healthcare
The account links the interruption of care directly to the withholding of tax revenues by Israel. The PA administers many healthcare referrals and payments for Palestinians in the occupied territories; when those funds are withheld or delayed, the PA’s capacity to pay for specialist treatment abroad or to finance services inside the West Bank is severely constrained.
- Diagnosis: cancer first identified in 2020.
- Location at outbreak of conflict: receiving treatment in Ramallah in October 2023.
- Consequence: treatment interrupted as the PA cannot fund care after tax revenues were withheld.
The report also notes that while the patient escaped the immediate hazards of the Gaza conflict — such as bombardment and a collapse of local health infrastructure — she remains vulnerable to a different form of medical exclusion caused by political and fiscal measures.
Wider context and claims
The article frames the patient’s experience as indicative of broader effects of the conflict beyond Gaza, asserting that the harm extends into the West Bank. Such characterisations were presented in the source material as an interpretation of the situation; they reflect concerns voiced by patients and observers about the indirect humanitarian impact of fiscal and security policies.
Independent verification of the individual case details beyond what has been reported here is not publicly available from the source material. The account highlights how interruptions to transfers and administrative funding mechanisms can produce immediate health consequences for people requiring time-sensitive treatment.
| Year / Period | Event |
|---|---|
| 2020 | Initial cancer diagnosis |
| October 2023 | Was in Ramallah receiving treatment when conflict escalated |
| 2024–2026 | Reported interruption to treatment as PA funding constrained by withheld revenues |
The case underlines the legal and ethical dilemmas that arise when financial levers are used in a conflict context. For patients with serious illnesses, delays in chemotherapy, radiotherapy or surgical interventions can substantially alter outcomes.
Journalists and human rights organisations have previously documented how restrictions on movement, damage to medical facilities and funding shortfalls have affected healthcare in both Gaza and the occupied West Bank. The account cited here adds a personal testimony to those broader records, showing how a patient can be displaced from immediate physical danger yet still be deprived of life-preserving medical care because of administrative and fiscal constraints.
Claims that the conflict constitutes or amounts to “genocide” were presented in the original piece as part of its framing. Such assertions are matters of intense political and legal debate and would require rigorous independent investigation and adjudication to determine their applicability under international law.
No charges or legal proceedings arising directly from the specifics of this individual patient’s case are reported in the source material.
*Name withheld in the original reporting.
